BC Children's Hospital Research Institute is pleased to congratulate the recipients of the 2018 Outstanding Achievement Awards and the 2018 BCCHR Studentships and Fellowships.
My disease-specific focus is neuroblastoma, the most common extra-cranial solid tumor of childhood. I am interested in older children and adolescents with neuroblastoma, who have more indolent disease but ultimately poor outcomes, and children with central nervous system involvement. Utilization of International Neuroblastoma Risk Group (INRG) data on more than 8,000 children has allowed me to study these rare subgroups and to determine if accepted prognostic factors and treatment approaches are applicable to them.
I also study late effects of cancer and its treatment in survivors of childhood, adolescent and young adult cancer. I am currently involved in a project that will determine if survivors are at increased risk for using prescription mental health drugs, compared to their peers.
Finally, I am interested in developing early phase clinical trials in pediatric oncology to help facilitate the rapid transition of new targeted drug therapies from the lab to the patient.
Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma
Journal of Pediatric Hematology/Oncology
Alexandra E. Foran, Helen R. Nadel, Anna F. Lee, Kerry J. Savage, Rebecca J. Deyell
Optimization of liposomal topotecan for use in treating neuroblastoma
Lina Chernov, Rebecca J. Deyell, Malathi Anantha, Nancy Dos Santos, Roger Gilabert-Oriol, Marcel B. Bally
ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma.
Marr KC, Connors JM, Savage KJ, Goddard KJ, Deyell RJ
ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors.
Alassiri AH, Ali RH, Shen Y, Lum A, Strahlendorf C, Deyell R, Rassekh R, Sorensen PH, Laskin J, Marra M, Yip S, Lee CH, Ng TL
Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.
Cold Spring Harbor Molecular Case Studies
Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
Görges M, West N, Deyell R, Winton P, Cheung W, Lauder G
Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.
Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, Cohn SL, Pearson AD, London WB, Matthay KK
Paroxysmal nocturnal haemoglobinuria phenotype cells and leucocyte subset telomere length in childhood acquired aplastic anaemia.
Tutelman PR, Aubert G, Milner RA, Dalal BI, Schultz KR, Deyell RJ
Antidepressant use among survivors of childhood, adolescent and young adult cancer: a report of the Childhood, Adolescent and Young Adult Cancer Survivor (CAYACS) Research Program.
Pediatric Blood & Cancer
Antidepressant use among survivors of childhood, adolescent, and young adult cancer: Letter to the editor responseLetter to the Editor
Pediatric Blood & Cancer
Rebecca J. Deyell, Maria Lorenzi, John J. Spinelli, Mary L. McBride
Immunosuppressive therapy without hematopoietic growth factor exposure in pediatric acquired aplastic anemia.
Deyell RJ, Shereck EB, Milner RA, Schultz KR
Low oxygen saturation by pulse oximetry may be associated with a low oxygen affinity hemoglobin variant, hemoglobin Titusville.
Deyell R, Jackson S, Spier S, Le D, Poon MC
Prevalence and Predictors of Antidepressant Users among Survivors of Childhood, Adolescent and Young Adult (AYA) Cancer
Five year survivors of childhood and AYA cancer are at risk for many chronic and late-occurring medical conditions including second malignancies and late mortality. They may also be at risk for adversely affected mental health status, although the psychological sequelae of cancer and its therapy remain poorly defined. Through the Childhood, Adolescent and Young Adult Cancer Survivors (CAYACS) research program, we utilize database linkage technology to determine if cancer survivors have an increased likelihood of being antidepressant medication users, compared to an age and gender-matched general population comparison group. We also evaluate which cancer diagnoses and treatment modalities are predictive of requiring prescription antidepressant medications among survivors.
Neuroblastoma in Older Children, Adolescents and Young Adults
Neuroblastoma is the most common extra-cranial solid tumor of childhood and accounts for 10% of pediatric cancer mortality. Its incidence peaks in infancy, with a median age at diagnosis of 17 months. Older children and adolescents with neuroblastoma are rare and typically have an indolent disease course but ultimately poor survival outcomes. In this study, we utilize data from the International Neuroblastoma Risk Group (INRG) on 8,800 children with neuroblastoma to determine if there is an optimal age cut-off greater than 18 months that defines this group and to define the clinical and biological predictors of overall and event-free survival. We also determine whether currently accepted treatment approaches for high-risk neuroblastoma are effective for these patients.Grants
Clinician Investigator Program, University of British Columbia, 2009-2011Honours & Awards
John Snow Prize, Epidemiologic methods, University of British Columbia, November 2010
Laura MacRae Subspecialty Resident Award, BC Children’s Hospital, 2010Research Group Members
Danielle Cohen, Undergraduate Student